Compare
Vivani Medical, Inc. vs Axogen, Inc. vs Conmed Corp vs Positron Corp
| Latest fiscal year | Vivani Medical, Inc. VANI | Axogen, Inc. AXGN | Conmed Corp CNMD | Positron Corp POSC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $0 | $225.21M | $1.37B | $461.5K |
| Revenue growth (YoY) | n/a | +20.2% | +5.2% | -21.5% |
| Gross margin | n/a | 74.3% | 54.6% | -458.2% |
| Operating margin | n/a | -3.5% | 7.5% | n/m |
| Net margin | n/a | -7.0% | 3.4% | n/m |
| Net income | -$26.61M | -$15.70M | $47.05M | -$10.60M |
| EPS (Diluted) | -$0.43 | -$0.34 | $1.51 | -$0.34 |
| Operating cash flow | -$24.32M | $812.0K | $170.69M | -$4.70M |
| Free cash flow | -$25.49M | -$2.93M | $150.88M | n/a |
| Cash & equivalents | $16.23M | $35.55M | n/a | n/a |
| Total assets | $39.39M | $221.69M | $2.33B | $4.00M |
| Total liabilities | $23.66M | $92.84M | $1.29B | $2.56M |
| Shareholders' equity | $15.73M | $128.85M | $1.03B | $1.44M |
| Return on year-end equity | -169.2% | -12.2% | 4.6% | -734.4% |
| Shares outstanding | 76.43M | 47.20M | n/a | 32.80M |
Revenue, most recent five fiscal years
| Fiscal year | Vivani Medical, Inc. | Axogen, Inc. | Conmed Corp | Positron Corp |
|---|---|---|---|---|
| Latest | $0 Ended 2025-12-31 | $225.21M Ended 2025-12-31 | $1.37B Ended 2025-12-31 | $461.5K Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2024-12-31 | $187.34M Ended 2024-12-31 | $1.31B Ended 2024-12-31 | $587.5K Ended 2024-12-31 |
| 2 years earlier | n/a | $159.01M Ended 2023-12-31 | $1.24B Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | $138.58M Ended 2022-12-31 | $1.05B Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $127.36M Ended 2021-12-31 | $1.01B Ended 2021-12-31 | n/a |